Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain

Maria Mareque,1 Pau Montesinos,2 Patricia Font,3 José María Guinea,4 Adolfo de la Fuente,5 Javier Soto,6 Itziar Oyagüez,1 James Brockbank,7 Tamara Iglesias,6 Julia Llinares,6 Jorge Sierra8 1Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain; 2H...

Full description

Bibliographic Details
Main Authors: Mareque M, Montesinos P, Font P, Guinea JM, de la Fuente A, Soto J, Oyagüez I, Brockbank J, Iglesias T, Llinares J, Sierra J
Format: Article
Language:English
Published: Dove Medical Press 2021-04-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
cost-effectiveness
gemtuzumab ozogamicin
acute myeloid leukaemia
spain
Online Access:https://www.dovepress.com/cost-effectiveness-analysis-of-gemtuzumab-ozogamicin-for-first-line-tr-peer-reviewed-fulltext-article-CEOR

Internet

https://www.dovepress.com/cost-effectiveness-analysis-of-gemtuzumab-ozogamicin-for-first-line-tr-peer-reviewed-fulltext-article-CEOR

Similar Items